Related Experiment Video
Updated: May 6, 2026
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Radiotherapy and surgery remain effective treatment options for retroperitoneal MPNST: a retrospective study based on
Zhe Xi1, Zhuang Aobo1, Xi Li2
1School of Medicine, Cancer Research Center, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, China.
Introduction:
The proportion of retroperitoneal malignant peripheral nerve sheath tumours (RMPNST) in retroperitoneal tumors is less than 5%, but the mortality rate is very high. However, there is no relevant research focused on RMPNST only.
Methods:
We retrospectively analyzed data from the SEER database of patients with primary RMPNST from 2000 to 2019, by leveraging the advantages of the Seer database, we can explore the prognosis of such rare diseases. Kaplan-Meier method was used to construct the survival curve, and cox regression model was used to analyze the factors affecting the prognosis of patients. In addition, a model was developed to distinguish high-risk and low-risk patients.
Results:
This study included a total of 52 patients, with a median survival time of 39 months (95% CI 12.740-65.260) and a 5-year survival rate of 44.2% (95% CI 0.299-0.565). Radiotherapy (p = 0.004, OR: 1.475, 95% CI 0.718-3.033), metastasis disease (p = 0.002, OR: 5.596, 95% CI 2.449-47.079) and surgery (p = 0.003, OR: 5.003, 95% CI 0.011-0.409) were associated with overall survival (OS). The 5-year distant metastasis rate was 36% (95% CI 0.221-0.499). We used the above risk factors to separate patients into high and low groups and evaluate the results through the receiver operating characteristic (ROC) curve. This model is beneficial for guiding the selection of treatment strategies.
Conclusion:
The majority of RMPNST patients have a good prognosis after surgery, and the establishment of high-low group is helpful for clinical decision-making.
Insights
Retroperitoneal malignant peripheral nerve sheath tumors (RMPNST) have a high mortality rate. This study identified factors like metastasis and surgery that impact survival, aiding in risk stratification for better treatment decisions.
Area of Science:
- Oncology
- Surgical Pathology
- Medical Statistics
Background:
- Retroperitoneal malignant peripheral nerve sheath tumors (RMPNST) are rare, comprising less than 5% of retroperitoneal tumors.
- Despite their rarity, RMPNSTs are associated with a very high mortality rate.
- Limited research exists specifically focusing on the prognosis and management of RMPNST.
Purpose of the Study:
- To investigate the prognostic factors and survival outcomes of primary retroperitoneal malignant peripheral nerve sheath tumors (RMPNST).
- To leverage the SEER database for a comprehensive analysis of a rare oncological condition.
- To develop a predictive model for stratifying RMPNST patients into high-risk and low-risk groups.
Main Methods:
- Retrospective analysis of patient data from the SEER database (2000-2019).
- Kaplan-Meier method for survival curve construction.
- Cox regression model to identify factors influencing overall survival (OS).
- Development and validation of a risk stratification model using ROC curve analysis.
Main Results:
- The study included 52 patients with a median survival of 39 months and a 5-year OS rate of 44.2%.
- Factors significantly associated with OS included radiotherapy, metastatic disease, and surgical intervention.
- A risk stratification model was developed, demonstrating utility in guiding treatment strategies.
Conclusions:
- The majority of RMPNST patients experience a favorable prognosis following surgical intervention.
- The developed high-low risk group model is a valuable tool for clinical decision-making in RMPNST management.
- Further research and data collection are warranted for this rare malignancy.
